March 5, 2019
Jamie Blundell, President & COO is pleased to provide the following update on CB2 Insights, one of CGOC’s private holdings:
CB2 Insights (“CB2”) one of the private portfolio holdings, announced on March 1, 2019, that it had completed a reverse take-over transaction with MVC Technologies Inc., and has been issued conditional listing approval from the Canadian Securities Exchange for the listing of the Company’s common shares. The common shares are expected to commence trading on March 6, 2019, under the ticker symbol “CBII”.
CGOC invested in CB2 in June of 2018, for a total of $400,004 for 909,100 units consisting of one common share and one-half of one common share purchase warrant (each a “Warrant”), where each whole Warrant entitles the holder to purchase one common share at a price of $0.50 for a period of two years from the initial closing date of June 21, 2018.
Jamie Blundell, President and Chief Operating Officer of CGOC commented, “We are very pleased with the maturation of this investment, and happy to see the CB2 team advancing their operations. This is a great example of how quickly one of the privately held investments can advance towards their public listing in under 12 months.”
CB2 works to help mainstream cannabis into traditional healthcare through objective, real-world evidence driven from its wholly-owned clinical arm. With more than 300,000 patient interactions to-date, the company is able to apply standard data collection protocols and track the efficacy of cannabis treatments in a way currently not available within the cannabis industry today. The Company owns and operates the largest and longest-running, multi-state medical cannabis evaluation and education center serving 12 states across the US. The Company has an aggressive medical cannabis clinic consolidation strategy and anticipates further announcements in this regard in the coming quarters.
For further information please contact Cannabis Growth Opportunity Corporation:
|Website: www.cgocorp.com||Investor Relations Email: firstname.lastname@example.org|
About CB2 Insights
CB2 Insights has a mission to mainstream medical cannabis into traditional healthcare. We do so by gathering data and creating objective real-world evidence through our proprietary software and clinical service brands. Using clinical management and data collection software at the point-of-care, CB2 Insights and its group of sub-brands has become a leading force behind bringing traditional healthcare protocols to the rapidly evolving global cannabis industry. To date, the Company has collected data from more than 300,000 patient interactions.
For more information on CB2 Insights follow this link www.cb2insights.com